Cyclocreatine phosphate dilithium
Cyclocreatine phosphate dilithium is a synthetic intracellular energy buffer. Cyclocreatine phosphate dilithium mediates antiproliferative activity in cells with high creatine kinase levels and inhibits solid tumor growth. Cyclocreatine phosphate dilithium maintains adenosine triphosphate (ATP) levels and protects tissues from hypoxia, cellular damage and inflammation during ischemic events. Cyclocreatine phosphate dilithium accumulates in skeletal muscle, reduces muscle phosphocreatine and total creatine levels, and acts both as a bioenergetic/anti-inflammatory agent and an experimental tool for the assessment of ischemic injury. Cyclocreatine phosphate dilithium can be used in studies related to solid tumors, heart failure and ischemia.
For research use only. We do not sell to patients.
- CAS No.: 63784-08-7
- Formula: C5H8Li2N3O5P
- Molecular Weight:234.99
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Cyclocreatine phosphate (dilithium) is taken up by and inhibits the growth of high-CK solid tumor cell lines, with antiproliferative specificity and potency similar to cyclocreatine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cyclocreatine phosphate (0.8 g/kg/day; intraperitoneal injection; administered daily for 14 consecutive days) dilithium shows no cardiotoxicity in healthy Wistar rats, with all tested cardiac parameters remaining normal[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (adult male, 6-8 weeks old, 180-220 g; isoproterenol-induced heart failure); Wistar albino (adult male, 170-190 g; isoproterenol-induced heart failure)[2]
-
Dosage:0.4 g/kg/day (prophylactic); 0.8 g/kg/day (prophylactic, therapeutic, toxicity control); 1.2 g/kg/day (prophylactic)
-
Administration:i.p.; daily; 14 days (prophylactic, therapeutic, toxicity control); i.p.; daily; 14 days starting 1 h after second isoproterenol dose (therapeutic)
-
Result:Prophylactically prevented isoproterenol-induced heart failure in rats.
Resuscitated poorly functioning hearts, with all doses restoring ejection fraction, reducing cardiac biomarkers and remodeling, and maintaining normal physical activity without cardiac toxicity.
Chemical Information
-
CAS No. 63784-08-7
-
Molecular Weight 234.99
-
Formula C5H8Li2N3O5P
-
SMILES
O=C(CN1C(N(P(O[Li])(O[Li])=O)CC1)=N)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Schimmel L, et al. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. Anticancer Res. 1996;16(1):375-380. [Content Brief]
[2]. Elgebaly SA, et al. Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and Protects against Development of Heart Failure. Pharmaceuticals (Basel). 2023;16(3):453. Published 2023 Mar 16. [Content Brief]
[3]. Turner DM, et al. Enhanced ability of skeletal muscle containing cyclocreatine phosphate to sustain ATP levels during ischemia following beta-adrenergic stimulation. J Biol Chem. 1987;262(14):6605-6609. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cyclocreatine phosphate dilithium Related Classifications
HY-148150A Related Classifications
Powered by Bioz